By Anthony O. Goriainoff
EKF Diagnostics Holdings PLC said Wednesday that its performance in the first quarter of 2022 was strong, with revenue in line with the year-prior period.
The AIM-listed medical company added that it remains on track to deliver results for 2022 in line with market views.
The company didn’t give any figures for 2022. However, pretax profit is seen at 10.0 million pounds ($12.5 million) compared with GBP21.4 million in 2021, taken from FactSet and based on two analysts’ forecasts. Revenue consensus for the year is GBP61.8 million, also taken from FactSet and based on three analysts’ estimates.
buy neurontin generic buybloinfo.com/neurontin.html over the counter
The company said it has a demand-driven pipeline of opportunities that is expected to start performing strongly once the investment in new fermenters at the Life Sciences business in its South Bend, Indiana, facility is completed by the end of 2022. It added that it was on track to have the capacity in place to support significant revenue growth through to 2024.
Shares at 0742 GMT were up 0.40 pence, or 1.2%, at 35 pence.
Write to Anthony O. Goriainoff at [email protected]
Credit: www.marketwatch.com /